Oceana Group Limited (OCGPF)
OTCMKTS · Delayed Price · Currency is USD
3.000
+0.432 (16.82%)
At close: Dec 30, 2025
Oceana Group Revenue
In the fiscal year ending September 30, 2025, Oceana Group had annual revenue of 10.00B ZAR, down -0.66%. Oceana Group had revenue of 4.81B in the half year ending September 30, 2025, a decrease of -12.39%.
Revenue
10.00B ZAR
Revenue Growth
-0.66%
P/S Ratio
0.71
Revenue / Employee
n/a
Employees
n/a
Market Cap
408.01M USD
Revenue Chart
* This company reports financials in ZAR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 10.00B | -66.00M | -0.66% |
| Sep 30, 2024 | 10.06B | 74.00M | 0.74% |
| Sep 30, 2023 | 9.99B | 1.84B | 22.57% |
| Sep 30, 2022 | 8.15B | 852.11M | 11.68% |
| Sep 30, 2021 | 7.30B | -1.01B | -12.19% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| South Dakota Soybean Processors, LLC | 484.17M |
| Hanover Foods | 330.81M |
| Elamex SA de CV | 110.74M |
| Cuisine Solutions | 80.48M |
| Armanino Foods of Distinction | 73.15M |
| Microalliance Group | 22.88M |
| Cordyceps Sunshine Biotech Holdings | 1.25M |
| Goldenwell Biotech | 62.34K |
Oceana Group News
- 2 months ago - Oceana Group Limited (OCGPF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Oceana Group Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 5 months ago - Oceana Group Limited - Special Call - Seeking Alpha
- 5 months ago - Press Release: Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis - Benzinga
- 1 year ago - Oceana Group Limited to Present at the Small Cap Growth Virtual Investor Conference December 5th - GlobeNewsWire